Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07778667) titled 'A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease' on Aug. 18.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Idorsia Pharmaceuticals Ltd.
Condition:
Fabry Disease
Intervention:
Drug: Lucerastat
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: September 2026
Target Sample Size: 16
To know more, visit https://clinicaltrials.gov/study/NCT07778667
Disclaimer: Curated by HT Syndication...